ClinicalTrials.gg
TerminatedNCT03168438Updated Jan 11, 2022Results posted

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

A Phase 1 interventional study of Letetresgene autoleucel and Letetresgene autoleucel with pembrolizumab in Neoplasms, sponsored by GlaxoSmithKline. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-11.

Primary conditionMultiple MyelomaRegistry: NeoplasmsReclassifiedWhy we changed it
Registry
Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Multiple Myeloma
Why
  1. The study's title name Multiple Myeloma, a narrower term within Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Why this study was terminated
The study was terminated following an internal review of the company's research and development portfolio

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pembrolizumab in Multiple Myeloma — none open to participants now, none under way, none of them phase 3. pembrolizumab · Multiple Myeloma.

Enrollment
12th of 17
6 · median 13
Started
2017
the only one that year
Phase 1
2 of 17
none open now
Registered
10th of 17
by date

Among the 17 studies testing pembrolizumab in Multiple Myeloma, this one is the 12th largest by enrollment, is the only one that started in 2017, is one of 2 in phase 1, and was the 10th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

None of the 17 studies testing pembrolizumab in Multiple Myeloma is open now. The open studies under Multiple Myeloma, anywhere →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pembrolizumab in Multiple Myeloma as a file.
02

Study summary

This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.

03

Conditions studied

  • Neoplasms

Browse trials for

Keywords

  • Relapsed and Refractory Multiple Myeloma
  • T Cell Receptor
  • Immuno-oncology
  • NY-ESO-1
  • Leukapheresis
  • Adoptive TCR T-cell therapy
  • Letetresgene autoleucel
04

In context

Multiple Myeloma Reclassified

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

This study's enrollment of 6 is below the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.

Browse Multiple Myeloma studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Multiple Myeloma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years of age or older on the date of signing .
  • confirmed diagnosis of secretory multiple myeloma with myeloma markers at levels defined in the protocol.
  • Documented diagnosis of multiple myeloma (RRMM) (at least 3 prior regimens and responsive to at least 1, and refractory to most recent prior therapies, which must have included one or more than one drug from each of the following drug classes: an immunomodulatory imide drug (IMiD), proteasome inhibitor, alkylator (unless the participant is ineligible or to receive an alkylator), CD 38 monoclonal antibody, and as separate lines or a combined .- (LVEF) >= 50%. Lower LVEF (>= 40%) permissible if formal cardiologic evaluation reveals no evidence for functional impairment.
  • Meets protocol criteria for patients who have previously received or other immuno-oncology agents.
  • Performance Status 0 or 1.
  • Participant is HLA-A*02:01, HLA-A*02:05, and/or HLA-A*02:06 positive as determined by a designated central laboratory.
  • Participant has confirmed sufficient expression of NY-ESO-1 and/or LAGE-1a as determined by a designated central laboratory.
  • In the Investigator's opinion, the participant is fit for cell collection.
  • Participant has adequate organ function and cell counts as described in the protocol.
  • Participants previously treated with BCMA therapy (BCMA chimeric antigen receptor (CAR)-T, antibody-drug conjugate (ADC), or other type of BCMA-targeted therapy) must have progressed from this therapy prior to attending the Baseline visit prior to beginning lymphodepletion.
  • use by male and female participant meets protocol requirements.

Exclusion criteria

Exclusion Criteria:

  • Has only plasmacytomas, plasma cell leukemia, monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), non-secretory myeloma or primarily amyloidosis.
  • Previously received anti- programmed death (PD)-1, anti-PD-ligand (L)1, or inhibitor.
  • Previously participated in Merck pivotal trial NCT02576977: Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab in or RRMM.
  • Had a prior stem cell transplant.
  • Has ongoing toxicity from previous anticancer therapy.
  • Had a major surgery within 4 weeks prior to enrollment.
  • Has history of allergic reactions to fludarabine, cyclophosphamide or agents similar to fludarabine, cyclophosphamide or other agents used in the study.
  • Known history of myelodysplasia.
  • Current active liver or biliary disease.
  • Known history of chronic active hepatitis or liver cirrhosis.
  • Participant has an active viral infection.
  • History of severe immune disease, including non-infectious pneumonitis, requiring or other treatments.
  • Active immune-mediated diseases.
  • Prior or active demyelinating disease.
  • Evidence or history of significant cardiac disease.
  • Evidence or history of other significant, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease.
  • Participants with concomitant second (except adequately treated non-melanomatous skin cancers, carcinoma in situ of the breast, treated superficial bladder cancer or prostate cancer, or in situ cervical cancers ) not in complete remission.
  • Known active central nervous system (CNS) and/or carcinomatous meningitis. Participants with previously treated may be eligible.
  • Active bacterial or systemic viral or fungal infections.
  • Pregnant or breastfeeding.
  • Cannot meet for prior radiotherapy, chemotherapy or other protocol-specified therapies.
  • More than 2 years have passed since the participant's last leukapheresis collection.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Arm 1: Letetresgene autoleucel (GSK3377794)

    Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.

    Drug: Letetresgene autoleucel · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    Arm 2: Letetresgene autoleucel (GSK3377794) with pembrolizumab

    Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive letetresgene autoleucel (GSK3377794), as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy, followed by pembrolizumab 200 mg every 3 weeks.

    Drug: Letetresgene autoleucel with pembrolizumab · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Pembrolizumab

Interventions

  • Letetresgene autoleucel (GSK3377794) as an IV infusion

  • DrugLetetresgene autoleucel with pembrolizumab

    Drug pages: Letetresgene autoleucel · Pembrolizumab

    Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks

  • Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.

  • Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.

  • Pembrolizumab is available as an IV infusion

07

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant who received a study treatment and the event need not necessarily have a causal relationship with study treatment. An SAE is any AE that results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in a persistent or significant disability; is a congenital anomaly/birth defect; is clinically significant or requires intervention to prevent one of the outcomes listed before.

    Time frame: Up to 108 weeks

  2. Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only

    The following toxicities were considered to be treatment limiting toxicities: any \>=Grade 4 AE; Grade 3 non-infectious pneumonitis and any other Grade 3 AE (excluding pneumonitis), that did not improve to Grade 2 within 7 days after onset despite medical management and supportive care. Exceptions included the following: Grade 3 or 4 leukopenia, lymphopenia, neutropenia, or febrile neutropenia; Grade 3 or 4 thrombocytopenia not associated with significant bleeding; Grade 3 anemia; Grade 4 cytokine release syndrome (CRS) or toxicities related to CRS that resolved to Grade \<=2 within 7 days; other Grade 3 laboratory abnormality determined to be not clinically significant by the Investigator; Grade 3 or 4 fever and chills; Grade 3 or 4 hypoalbuminemia or abnormal electrolytes that responded to supplementation/correction; AE related to the cancer or its progression.

    Time frame: Up to 3 weeks

  3. Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline

    Blood samples were collected for the assessment of following clinical chemistry parameters: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, phosphate, sodium and calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.

    Time frame: Up to 108 weeks

  4. Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline

    Blood samples were collected for the assessment of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Laboratory parameters were graded according to NCI-CTCAE version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.

    Time frame: Up to 108 weeks

  5. Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline

    Blood samples were collected for the assessment of following coagulation parameters: prothrombin time and partial thromboplastin time (PTT). A laboratory value that is outside the normal range is considered either high abnormal (value above the upper limit of the normal range) or low abnormal (value below the lower limit of the normal range). Participants were counted twice if the participant had values in 'Decreased to low' and 'Increased to high' during the post-Baseline period. Data for worst case post Baseline is presented.

    Time frame: Up to 108 weeks

  6. Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings

    ECG was recorded using an ECG machine that automatically calculated the heart rate and measured PR, RR, QRS and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

    Time frame: Up to 108 weeks

Secondary outcomes

  1. Overall Response Rate

    Overall response rate is defined as the percentage of participants with a best overall response (BOR) of confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) Response Criteria (2016); where, PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 milligrams (mg) per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: CR as defined by normal free light chain (FLC) ratio and absence of clonal cells by immunohistochemistry. Confidence intervals were calculated using the exact (Clopper-Pearson) method.

    Time frame: Up to 108 weeks

  2. Time to Response

    Time to response is defined as the time interval (in months) from T-cell infusion to initial date of documented confirmed response (PR or better) in the subset of participants who showed a confirmed BOR of PR or better by Investigator assessment per IMWG (2016).

    Time frame: Up to 108 weeks

  3. Duration of Response

    Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).

    Time frame: Up to 108 weeks

  4. Progression-free Survival

    Progression Free Survival is defined as the interval between the date of T-cell infusion and the initial assessment date of confirmed progressive disease as assessed by the investigator per IMWG (2016) or date of death. Progressive disease is defined as an increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>=0.5 grams per deciliter (g/dL); Serum M-protein increase \>=1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>=200 mg per 24 hours).

    Time frame: Up to 108 weeks

  5. Maximum Persistence (Cmax) of GSK3377794

    Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in deoxyribonucleic acid (DNA) extracted from peripheral blood mononuclear cell (PBMC).

    Time frame: Up to 108 weeks

  6. Time to Maximum Persistence

    Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.

    Time frame: Up to 108 weeks

  7. Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])

    Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.

    Time frame: Up to Day 28

08

Results

Posted Jan 11, 2022

Participant flow

This was a pilot study to assess safety and tolerability of genetically engineered New York esophageal squamous cell carcinoma 1 (NY-ESO-1) (c259) T Cells Alone or in combination with pembrolizumab in participants with relapsed/refractory multiple myeloma. The study was conducted in the United States.

Participant flow — Overall Study
MilestoneGSK3377794GSK3377794+Pembrolizumab
Started33
Completed32
Not completed01
Withdrew: Long term follow-up declined, study terminated by sponsor01

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant or clinical investigation participant who received a study treatment and the event need not necessarily have a causal relationship with study treatment. An SAE is any AE that results in death; is life-threatening; requires hospitalization or prolongation of existing hospitalization; results in a persistent or significant disability; is a congenital anomaly/birth defect; is clinically significant or requires intervention to prevent one of the outcomes listed before.

Time frame:
Up to 108 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsGSK3377794GSK3377794+Pembrolizumab
Any AE33
Any SAE22
PrimaryNumber of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only

The following toxicities were considered to be treatment limiting toxicities: any \>=Grade 4 AE; Grade 3 non-infectious pneumonitis and any other Grade 3 AE (excluding pneumonitis), that did not improve to Grade 2 within 7 days after onset despite medical management and supportive care. Exceptions included the following: Grade 3 or 4 leukopenia, lymphopenia, neutropenia, or febrile neutropenia; Grade 3 or 4 thrombocytopenia not associated with significant bleeding; Grade 3 anemia; Grade 4 cytokine release syndrome (CRS) or toxicities related to CRS that resolved to Grade \<=2 within 7 days; other Grade 3 laboratory abnormality determined to be not clinically significant by the Investigator; Grade 3 or 4 fever and chills; Grade 3 or 4 hypoalbuminemia or abnormal electrolytes that responded to supplementation/correction; AE related to the cancer or its progression.

Time frame:
Up to 3 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only
ParticipantsGSK3377794+Pembrolizumab
Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm Only0
PrimaryNumber of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline

Blood samples were collected for the assessment of following clinical chemistry parameters: glucose, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, creatinine, potassium, magnesium, phosphate, sodium and calcium. Laboratory parameters were graded according to National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE) version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.

Time frame:
Up to 108 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to Baseline
ParticipantsGSK3377794GSK3377794+Pembrolizumab
Glucose (Hyperglycemia)22
Glucose (Hypoglycemia)00
Albumin (Hypoalbuminemia)32
ALP increased11
ALT increased01
AST increased01
Bilirubin increased01
Creatinine increased13
Potassium (Hyperkalemia)00
Potassium (Hypokalemia)12
Magnesium (Hypermagnesemia)00
Magnesium (Hypomagnesemia)21
Phosphate (Hypophosphatemia)22
Sodium (Hypernatremia)00
Sodium (Hyponatremia)21
Calcium (Hypercalcemia)10
Calcium (Hypocalcemia)23
PrimaryNumber of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline

Blood samples were collected for the assessment of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. Laboratory parameters were graded according to NCI-CTCAE version 4.03 where, Grade1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences. An increase in grade is defined as an increase in CTCAE grade relative to Baseline grade. Data for any grade increase at worst case post Baseline is presented.

Time frame:
Up to 108 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to Baseline
ParticipantsGSK3377794GSK3377794+Pembrolizumab
Hemoglobin (Anemia)23
Hemoglobin increased00
Lymphocyte count decreased33
Lymphocyte count increased00
Neutrophil count decreased33
Platelet count decreased33
Leukocyte count decreased33
PrimaryNumber of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline

Blood samples were collected for the assessment of following coagulation parameters: prothrombin time and partial thromboplastin time (PTT). A laboratory value that is outside the normal range is considered either high abnormal (value above the upper limit of the normal range) or low abnormal (value below the lower limit of the normal range). Participants were counted twice if the participant had values in 'Decreased to low' and 'Increased to high' during the post-Baseline period. Data for worst case post Baseline is presented.

Time frame:
Up to 108 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to Baseline
ParticipantsGSK3377794GSK3377794+Pembrolizumab
Prothrombin Time; decrease to low0—
Prothrombin Time; To normal or no change0—
Prothrombin Time; increase to high1—
PTT; decrease to low0—
PTT; To normal or no change1—
PTT; increase to high0—
PrimaryNumber of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings

ECG was recorded using an ECG machine that automatically calculated the heart rate and measured PR, RR, QRS and QT duration corrected for heart rate by Fridericia's formula (QTcF) intervals. Data for number of participants with abnormal clinically significant ECG findings for worst case post-Baseline has been presented. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame:
Up to 108 weeks
Reported as:
Count of participants · Participants
Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings
ParticipantsGSK3377794GSK3377794+Pembrolizumab
Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) Findings01
SecondaryOverall Response Rate

Overall response rate is defined as the percentage of participants with a best overall response (BOR) of confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) Response Criteria (2016); where, PR: \>=50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by \>=90% or to \<200 milligrams (mg) per 24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \<100 mg per 24 hours; CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<= 5% plasma cells in bone marrow; or sCR: CR as defined by normal free light chain (FLC) ratio and absence of clonal cells by immunohistochemistry. Confidence intervals were calculated using the exact (Clopper-Pearson) method.

Time frame:
Up to 108 weeks
Reported as:
Number · Percentage of participants
Overall Response Rate
Percentage of participantsGSK3377794GSK3377794+Pembrolizumab
Overall Response Rate33.3 (0.8 to 90.6)66.7 (9.4 to 99.2)
SecondaryTime to Response

Time to response is defined as the time interval (in months) from T-cell infusion to initial date of documented confirmed response (PR or better) in the subset of participants who showed a confirmed BOR of PR or better by Investigator assessment per IMWG (2016).

Time frame:
Up to 108 weeks
Reported as:
Median · Months
Time to Response
MonthsGSK3377794GSK3377794+Pembrolizumab
Time to Response0.7 (NA to NA)0.7 (0.7 to 0.7)
SecondaryDuration of Response

Duration of response is defined as the interval between the initial date of the confirmed response (sCR, CR, VGPR, or PR) and the initial assesment date of confirmed progressive disease or death among participants with a confirmed response per IMWG (2016).

Time frame:
Up to 108 weeks
Reported as:
Median · Months
Duration of Response
MonthsGSK3377794GSK3377794+Pembrolizumab
Duration of Response2.1 (NA to NA)2.1 (2.1 to 2.1)
SecondaryProgression-free Survival

Progression Free Survival is defined as the interval between the date of T-cell infusion and the initial assessment date of confirmed progressive disease as assessed by the investigator per IMWG (2016) or date of death. Progressive disease is defined as an increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \>=0.5 grams per deciliter (g/dL); Serum M-protein increase \>=1 g/dL if the lowest M-component was \>=5 g/dL; Urinary M-protein (absolute increase must be \>=200 mg per 24 hours).

Time frame:
Up to 108 weeks
Reported as:
Median · Months
Progression-free Survival
MonthsGSK3377794GSK3377794+Pembrolizumab
Progression-free Survival2.79 (1.31 to 5.16)2.78 (2.76 to 2.79)
SecondaryMaximum Persistence (Cmax) of GSK3377794

Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in deoxyribonucleic acid (DNA) extracted from peripheral blood mononuclear cell (PBMC).

Time frame:
Up to 108 weeks
Reported as:
Geometric mean · Copies per microgram genomic DNA
Maximum Persistence (Cmax) of GSK3377794
Copies per microgram genomic DNAGSK3377794GSK3377794+Pembrolizumab
Maximum Persistence (Cmax) of GSK337779438509.67 ± 160.589640.56 ± 84.8
SecondaryTime to Maximum Persistence

Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.

Time frame:
Up to 108 weeks
Reported as:
Median · Days
Time to Maximum Persistence
DaysGSK3377794GSK3377794+Pembrolizumab
Time to Maximum Persistence8.0 (5 to 15)8.0 (7 to 15)
SecondaryArea Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])

Blood samples were collected to measure persistence of infused GSK3377794 using polymerase chain reaction of a vector specific sequence in DNA extracted from PBMC.

Time frame:
Up to Day 28
Reported as:
Geometric mean · Days*Copies per microgram genomic DNA
Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])
Days*Copies per microgram genomic DNAGSK3377794GSK3377794+Pembrolizumab
Area Under the Plasma Concentration-time Curve From Zero to Day 28 (AUC[0-28])463989.35 ± 237.01498869.21 ± 90.4

Adverse events

Collected over Non-serious AEs and SAEs were collected up to 108 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK33777942/3 (66.7%)2/3 (66.7%)3/3 (100%)
GSK3377794+Pembrolizumab0/3 (0%)2/3 (66.7%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventGSK3377794GSK3377794+Pembrolizumab
PancytopeniaBlood and lymphatic system disorders1/31/3
Atrial flutterCardiac disorders0/31/3
BronchitisInfections and infestations1/30/3
PneumoniaInfections and infestations1/30/3
Back painMusculoskeletal and connective tissue disorders1/30/3
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/3
Most frequent other events
Showing 10 of 77
Most frequent other events
EventGSK3377794GSK3377794+Pembrolizumab
AnaemiaBlood and lymphatic system disorders3/33/3
ThrombocytopeniaBlood and lymphatic system disorders1/33/3
LeukopeniaBlood and lymphatic system disorders1/32/3
LymphopeniaBlood and lymphatic system disorders1/32/3
NeutropeniaBlood and lymphatic system disorders1/32/3
FatigueGeneral disorders1/32/3
Oedema peripheralGeneral disorders1/32/3
PyrexiaGeneral disorders1/32/3
DiarrhoeaGastrointestinal disorders2/32/3
NauseaGastrointestinal disorders0/32/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK3377794GSK3377794+PembrolizumabTotal
Mean66.0 ± 11.2764.3 ± 2.5265.2 ± 7.36
Sex: Female, Male
Sex: Female, Male(Participants)GSK3377794GSK3377794+PembrolizumabTotal
Female000
Male336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK3377794GSK3377794+PembrolizumabTotal
White336
09

Study locations

5 sites
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Tampa, Florida 33612-9497, United States
  • GSK Investigational Site
    Atlanta, Georgia 30322, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Jul 2020, 34 months.

Results were first posted in Jan 2022, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
May 30, 2017
StartActual
Aug 18, 2017
Primary completionActual
Jul 13, 2020
CompletionActual
Nov 5, 2020
Results first posted
Jan 11, 2022
Last update
Jan 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03168438
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 30, 2017
Start date
Aug 18, 2017
Primary completion
Jul 13, 2020
Completion
Nov 5, 2020
Results posted
Jan 11, 2022
Last update
Jan 11, 2022

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Letetresgene autoleucel · Pembrolizumab

Start the discussion